Yale-New Haven Hospital
- Type
- Teaching hospital
- Where
- New Haven, CT
- Medicare CCN
- 070022
- Received
- $1,859,440 in 178 records, 2020 ($318,242 general, $1,541,197 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Business registration: Yale New Haven Hospital, Inc. Fuzzy (name and state)
- Nonprofit contractor: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Plan sponsor: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Federal award recipient: YALE NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying client: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
- Lobbying client: YALE-NEW HAVEN HOSPITAL, INC. Fuzzy (name and state)
- Lobbying registrant: YALE-NEW HAVEN HOSPITAL Fuzzy (name and state)
- Nonprofit: YALE NEW HAVEN HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 31 | $318,242 |
| 2020 | Research payment | 147 | $1,541,197 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 147 | $1,541,197 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 3 | $115,000 |
| Education | 2 | $54,666 |
| Grant | 4 | $47,599 |
| Gift | 10 | $47,522 |
| Space rental or facility fees (teaching hospital only) | 3 | $42,500 |
| Charitable Contribution | 9 | $10,954 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Stryker Corporation | $15,183 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,460 | Research payment | Cash or cash equivalent | Yale New Haven Hosp Constable Neuro Clinical MR | 2020 | |
| 2020-12-31 | Stryker Corporation | $2,401 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $990 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2016MRIPR1023Huber | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $871 | Research payment | Cash or cash equivalent | Yale2018MRIPR990Huber | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $675 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2019IPR925TurkBrowne | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $580 | Research payment | Cash or cash equivalent | Yale2019MRIPR990Huber | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $127 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2018MRIPR1066Constable | 2020 | |
| 2020-12-31 | Stryker Corporation | $15 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-23 | SEAGEN INC. | $50,884 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-12-23 | SEAGEN INC. | $9,350 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-12-23 | Blue Earth Diagnostics | $4,005 | Research payment | In-kind items and services | Axumin Drug, Diagnostic Imaging | Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases | 2020 |
| 2020-12-23 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-23 | SEAGEN INC. | $1,293 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-23 | SEAGEN INC. | $260 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-12-17 | Conformis, Inc. | $3,000 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-12-17 | Conformis, Inc. | $1,500 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-12-16 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-12-14 | SEAGEN INC. | $15,965 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-12-09 | SEAGEN INC. | $3,802 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-09 | SEAGEN INC. | $325 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-12-02 | Bracco Diagnostics Inc. | $10,350 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-12-02 | SEAGEN INC. | $5,240 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-02 | Conformis, Inc. | $5,200 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-12-02 | SEAGEN INC. | $2,859 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-12-02 | SEAGEN INC. | $2,162 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-11-20 | Bard Peripheral Vascular, Inc. | $2,860 | Research payment | Cash or cash equivalent | COVERA Device, BD Interventional - Peripheral Intervention | Lutonix AV PAS CL003301 | 2020 |
| 2020-11-18 | Pacira Pharmaceuticals Incorporated | $12,649 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-11-18 | Pacira Pharmaceuticals Incorporated | $1,032 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-11-17 | Blue Earth Diagnostics | $4,005 | Research payment | In-kind items and services | Axumin Drug, Diagnostic Imaging | Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases | 2020 |
| 2020-11-05 | JAZZ PHARMACEUTICALS INC. | $127,029 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-11-04 | Pacira Pharmaceuticals Incorporated | $390 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-11-03 | SEAGEN INC. | $39,430 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-11-03 | SEAGEN INC. | $4,324 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-11-03 | SEAGEN INC. | $2,406 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-11-02 | Blue Earth Diagnostics | $4,005 | Research payment | In-kind items and services | Axumin Drug, Diagnostic Imaging | Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases | 2020 |
| 2020-10-30 | TransMedics, Inc. | $1,690 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-10-29 | AngioDynamics, Inc. | $49,666 | Education | In-kind items and services | Nanoknife Device, Oncology Surgery | 2020 | |
| 2020-10-26 | Lilly USA, LLC | $60,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-10-20 | SEAGEN INC. | $9,204 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-10-20 | Vyaire Medical, Inc. | $1,950 | Research payment | Cash or cash equivalent | SuperNO2VA Device, Adult/Pediatric ventilation solutions | Multicenter Study of Saturation Targeting by Automated vs. Manual Adjustment of Inspired Oxygen in Neonates and Infants | 2020 |
| 2020-10-14 | SEAGEN INC. | $2,888 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-10-09 | Indivior Inc. | $1,594 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults | 2020 |
| 2020-10-09 | Indivior Inc. | $1,594 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Long-acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-involved Adults | 2020 |
| 2020-10-09 | Amgen Inc. | $239 | Research payment | In-kind items and services | Otezla Drug, Inflammation | I-SPY COVID TRIAL: An Adaptive Platform Trial to Reduce Mortality and Ventilator Requirements for Critically Ill Patient | 2020 |
| 2020-10-08 | Conformis, Inc. | $2,438 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-10-07 | Indivior Inc. | $544 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2020 |
| 2020-10-07 | Indivior Inc. | $544 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2020 |
| 2020-10-07 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-10-07 | SEAGEN INC. | $390 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-10-02 | Pacira Pharmaceuticals Incorporated | $9,100 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-10-02 | Pacira Pharmaceuticals Incorporated | $3,965 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-09-23 | Siemens Medical Solutions USA, Inc. | $17,825 | Research payment | Cash or cash equivalent | CorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopy | PRECISION GRX PMS | 2020 |
| 2020-09-22 | JAZZ PHARMACEUTICALS INC. | $101,623 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | CLINICAL CPX-351 INVESTIGATOR SPONSORED TRIALS | 2020 |
| 2020-09-18 | TransMedics, Inc. | $1,500 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-09-18 | AstraZeneca Pharmaceuticals LP | $25 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-09-17 | GlaxoSmithKline, LLC. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-09-11 | AstraZeneca Pharmaceuticals LP | $200 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-09-11 | AstraZeneca Pharmaceuticals LP | $50 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-09-11 | AstraZeneca Pharmaceuticals LP | $50 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-09-09 | VASCULAR SOLUTIONS, INC. | $15,927 | Research payment | Cash or cash equivalent | VASCULAR SOLUTIONS Device, Interventional Access | CTO Study Image Review | 2020 |
| 2020-09-08 | AstraZeneca Pharmaceuticals LP | $50 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-09-04 | SEAGEN INC. | $5,000 | Education | Cash or cash equivalent | ADCETRIS Biological, Oncology | 2020 | |
| 2020-09-04 | Eisai Inc. | $5,000 | Grant | Cash or cash equivalent | Lenvima Drug, Oncology | 2020 | |
| 2020-09-02 | Olympus America Inc. | $14,762 | Gift | In-kind items and services | 2020 | ||
| 2020-09-02 | Olympus America Inc. | $7,277 | Gift | In-kind items and services | 2020 | ||
| 2020-09-02 | Olympus America Inc. | $2,119 | Gift | In-kind items and services | 2020 | ||
| 2020-09-02 | Olympus America Inc. | $1,088 | Gift | In-kind items and services | 2020 | ||
| 2020-09-02 | Dexcom, Inc. | $374 | Research payment | In-kind items and services | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | VERY LOW CARBOHYDRATE DIETS (VLCD) IN YOUTH WITH TYPE 1 DIABETES | 2020 |
| 2020-09-02 | Olympus America Inc. | $71 | Gift | In-kind items and services | 2020 | ||
| 2020-09-02 | Dexcom, Inc. | $39 | Research payment | In-kind items and services | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | VERY LOW CARBOHYDRATE DIETS (VLCD) IN YOUTH WITH TYPE 1 DIABETES | 2020 |
| 2020-08-28 | Cepheid | $50,000 | Research payment | Cash or cash equivalent | GENEXPERT Device, MOLECULAR DIAGNOSTICS | 2020 | |
| 2020-08-27 | Olympus America Inc. | $125 | Gift | In-kind items and services | 2020 | ||
| 2020-08-24 | AstraZeneca Pharmaceuticals LP | $25 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-08-19 | Amgen Inc. | $5,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-08-18 | E.R. Squibb & Sons, L.L.C. | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-08-13 | Siemens Medical Solutions USA, Inc. | $870 | Research payment | Cash or cash equivalent | Yale2018MRIPR990Huber | 2020 | |
| 2020-08-13 | Siemens Medical Solutions USA, Inc. | $580 | Research payment | Cash or cash equivalent | Yale2019MRIPR990Huber | 2020 | |
| 2020-08-05 | Indivior Inc. | $1,103 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2020 |
| 2020-08-05 | Indivior Inc. | $1,103 | Research payment | In-kind items and services | SUBLOCADE Drug, OUD | Coordinating opioid use treatment through Medical Management with Infection Treatment (Project COMMIT) | 2020 |
| 2020-08-05 | Pacira Pharmaceuticals Incorporated | $390 | Research payment | Cash or cash equivalent | EXPAREL Drug, PAIN MANAGEMENT | A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A | 2020 |
| 2020-08-04 | SEAGEN INC. | $43,142 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-08-04 | SEAGEN INC. | $13,879 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-08-04 | SEAGEN INC. | $7,028 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-08-04 | Barco, Inc. | $4,477 | Gift (2 payments) | In-kind items and services | Device, diagnostic imaging | 2020 | |
| 2020-08-04 | SEAGEN INC. | $260 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-08-03 | Lilly USA, LLC | $5,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-07-27 | Genentech USA, Inc. | $35,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2020 | |
| 2020-07-23 | Cardiovascular Systems Inc. | $22,288 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-07-23 | Conformis, Inc. | $13,000 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-07-23 | SEAGEN INC. | $3,900 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-07-23 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-07-20 | Dexcom, Inc. | $1,123 | Research payment | In-kind items and services | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | CAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES | 2020 |
| 2020-07-20 | Dexcom, Inc. | $395 | Research payment | In-kind items and services | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | CAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES | 2020 |
| 2020-07-16 | Ipsen Biopharmaceuticals, Inc | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ONIVYDE Drug, Oncology | 2020 | |
| 2020-07-15 | VentureMed Group, Inc. | $1,800 | Research payment | Cash or cash equivalent | FLEX Scoring Catheter Device, Vascular | FLEX-AV Registry | 2020 |
| 2020-07-10 | Siemens Medical Solutions USA, Inc. | $110,996 | Research payment | Cash or cash equivalent | CorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopy | PRECISION GRX PMS | 2020 |
| 2020-07-09 | Cardiovascular Systems Inc. | $1,500 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-07-08 | Siemens Medical Solutions USA, Inc. | $2,250 | Research payment | Cash or cash equivalent | Sequoia Device, US - Ultrasound Systems | 3 releases of Sequoia system External Clinical Evaluation and Validation | 2020 |
| 2020-07-07 | Dexcom, Inc. | $19 | Research payment | In-kind items and services | DEXCOM G6 CGM SYSTEM Device, ENDOCRINOLOGY | CAPO: CONTINUOUS GLUCOSE MONITORING IN A2 GESTATIONAL DIABETES AND PREGNANCY OUTCOMES | 2020 |
| 2020-07-03 | Siemens Medical Solutions USA, Inc. | $3,000 | Research payment | Cash or cash equivalent | Sequoia Device, US - Ultrasound Systems | 3 releases of Sequoia system External Clinical Evaluation and Validation | 2020 |
| 2020-07-03 | Siemens Medical Solutions USA, Inc. | $1,500 | Research payment | Cash or cash equivalent | Sequoia Device, US - Ultrasound Systems | 3 releases of Sequoia system External Clinical Evaluation and Validation | 2020 |
| 2020-06-29 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-29 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-25 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-06-22 | SEAGEN INC. | $33,750 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-22 | SEAGEN INC. | $18,454 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-22 | SEAGEN INC. | $4,875 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-22 | SEAGEN INC. | $3,900 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-22 | SEAGEN INC. | $1,400 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-19 | TransMedics, Inc. | $2,346 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-06-09 | SEAGEN INC. | $2,308 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-06-09 | SEAGEN INC. | $780 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-06-08 | Siemens Medical Solutions USA, Inc. | $174,570 | Research payment | Cash or cash equivalent | CorPath GRX Device, AT - Fixed interventional x-ray/angiography fluoroscopy | PRECISION GRX PMS | 2020 |
| 2020-06-08 | SEAGEN INC. | $2,600 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-08 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-06-02 | SEAGEN INC. | $17,774 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-06-02 | SEAGEN INC. | $499 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-06-02 | SEAGEN INC. | $124 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-05-28 | Cepheid | $49,300 | Research payment | Cash or cash equivalent | GENEXPERT Device, MOLECULAR DIAGNOSTICS | 2020 | |
| 2020-05-27 | VASCULAR SOLUTIONS, INC. | $7,500 | Research payment | Cash or cash equivalent | VASCULAR SOLUTIONS Device, Interventional Access | CTO Study Image Review | 2020 |
| 2020-05-19 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-05-13 | SEAGEN INC. | $22,009 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-05-13 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-05-07 | Cardiovascular Systems Inc. | $750 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-05-06 | SEAGEN INC. | $7,028 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-05-06 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | TUKYSA Drug, Oncology | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 |
| 2020-05-06 | SEAGEN INC. | $750 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-05-06 | SEAGEN INC. | $728 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-05-06 | SEAGEN INC. | $124 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-05-05 | Hyperfine Research, Inc. | $50,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | In-kind items and services | Swoop Device, Portable MRI | 2020 | |
| 2020-05-04 | Optinose US, Inc. | $100 | Charitable Contribution | Cash or cash equivalent | Xhance Drug, Otolaryngology (Ear, Nose, Throat) | 2020 | |
| 2020-05-01 | TransMedics, Inc. | $500 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-05-01 | TransMedics, Inc. | $250 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | Heart Expand CAP | 2020 |
| 2020-05-01 | TransMedics, Inc. | $82 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-04-24 | E.R. Squibb & Sons, L.L.C. | $9,000 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-04-22 | SEAGEN INC. | $108,688 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-04-22 | SEAGEN INC. | $37,108 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-04-22 | SEAGEN INC. | $520 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-04-21 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-04-08 | Siemens Medical Solutions USA, Inc. | $127 | Research payment | Cash or cash equivalent | YaleNewHavenHosp2018MRIPR1066Constable | 2020 | |
| 2020-04-06 | Conformis, Inc. | $3,999 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-03-25 | SEAGEN INC. | $2,308 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-03-17 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-03-11 | SEAGEN INC. | $1,010 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-03-09 | SEAGEN INC. | $1,560 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-03-04 | SEAGEN INC. | $1,400 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-03-04 | SEAGEN INC. | $904 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-03-03 | Bracco Diagnostics Inc. | $2,070 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-02-26 | SEAGEN INC. | $904 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-02-25 | BioFire Diagnostics, LLC | $623 | Research payment | Cash or cash equivalent | BCID2 IUO Panel Kit (RFIT-ASY-0146) Device, Clinical Diagnostics | BCID2 MEP | 2020 |
| 2020-02-19 | SEAGEN INC. | $8,577 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-02-19 | SEAGEN INC. | $1,560 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-02-18 | SEAGEN INC. | $1,755 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-02-18 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-02-11 | Cepheid | $49,300 | Research payment | Cash or cash equivalent | GENEXPERT Device, MOLECULAR DIAGNOSTICS | 2020 | |
| 2020-02-07 | Bard Peripheral Vascular, Inc. | $1,726 | Research payment | Cash or cash equivalent | COVERA Device, BD Interventional - Peripheral Intervention | AVeNEW BPV14005 | 2020 |
| 2020-02-03 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-01-31 | GE HEALTHCARE | $1,454 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-01-29 | SEAGEN INC. | $6,262 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-01-29 | SEAGEN INC. | $372 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-01-28 | Bracco Diagnostics Inc. | $1,000 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-01-21 | SEAGEN INC. | $26,106 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A single-arm, open-label, multicenter study of enfortumab vedotin (ASG-22CE) for treatment of patients with locally adva | 2020 |
| 2020-01-21 | SEAGEN INC. | $1,079 | Research payment | Cash or cash equivalent | Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | 2020 | |
| 2020-01-20 | SEAGEN INC. | $21,635 | Research payment | Cash or cash equivalent | A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1 | 2020 | |
| 2020-01-16 | Conformis, Inc. | $1,500 | Research payment | Cash or cash equivalent | iTotal CR Device, ORTHOPAEDIC KNEE IMPLANTS | iTotal 12-005 | 2020 |
| 2020-01-15 | C. R. Bard, Inc. & Subsidiaries | $23,330 | Research payment | Cash or cash equivalent | Arctic Sun Device, Medical Systems | INTREPID BMD1111 | 2020 |
| 2020-01-15 | SEAGEN INC. | $11,711 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-01-14 | TransMedics, Inc. | $8,700 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | DCD Heart | 2020 |
| 2020-01-14 | TransMedics, Inc. | $5,200 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | Heart Expand CAP | 2020 |
| 2020-01-14 | TransMedics, Inc. | $500 | Research payment | Cash or cash equivalent | Organ Care System Device, DEVICE | Heart Expand CAP | 2020 |
| 2020-01-13 | Cepheid | $49,300 | Research payment | Cash or cash equivalent | GENEXPERT Device, MOLECULAR DIAGNOSTICS | 2020 | |
| 2020-01-08 | SEAGEN INC. | $11,320 | Research payment | Cash or cash equivalent | Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib | 2020 | |
| 2020-01-08 | SEAGEN INC. | $3,900 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2020 | |
| 2020-01-08 | SEAGEN INC. | $1,500 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | A Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Pembrolizumab and/or Che | 2020 |
| 2020-01-08 | SEAGEN INC. | $250 | Research payment | Cash or cash equivalent | Phase 1 study of SGN-CD48A in patients with relapsed or refractory multiple myeloma | 2020 | |
| 2020-01-07 | Bracco Diagnostics Inc. | $1,500 | Research payment | Cash or cash equivalent | MultiHance Drug, Diagnostic Imaging | An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Receive | 2020 |
| 2020-01-01 | ClearPoint Neuro, Inc. | $27,599 | Grant | In-kind items and services | ClearPoint System Device, Neurology | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In New Haven, CT, county South Central Connecticut Planning Region, CT, state Connecticut; placed by its city name.
| Measure | Place (city or town) New Haven, CT | County South Central Connecticut Planning Region, CT | State Connecticut |
|---|---|---|---|
| Population B01003 | 134,349 | 570,598 | 3,624,508 |
| Population, 2020 census P1 | 134,023 | - | 3,605,944 |
| Median age B01002 | 31.9 | 40.2 | 41.1 |
| Under 18 B01001 | 21.3% | 19.6% | 20.2% |
| 65 and over B01001 | 11.8% | 18.6% | 18.5% |
| Households B11001 | 54,773 | 230,673 | 1,434,007 |
| Foreign born B05002 | 18.0% | 13.7% | 15.7% |
| Median household income B19013 | $56,851 | $88,197 | $95,781 |
| Median family income B19113 | $68,668 | $115,384 | $122,706 |
| Per capita income B19301 | $36,242 | $49,766 | $55,915 |
| Poverty rate B17001 | 23.9% | 11.4% | 10.0% |
| Unemployment rate B23025 | 8.4% | 6.0% | 5.6% |
| Civilian labor force B23025 | 69,528 | 307,607 | 1,959,490 |
| Mean commute (minutes) B08013 | 21.5 | 23.5 | 26.5 |
| Bachelor's degree or higher B15003 | 38.9% | 42.0% | 42.5% |
| Housing units B25001 | 60,333 | 248,267 | 1,541,822 |
| Owner-occupied B25003 | 28.4% | 60.5% | 66.5% |
| Renters B25003 | 71.6% | 39.5% | 33.5% |
| Median home value B25077 | $287,100 | $353,100 | $366,900 |
| Median gross rent B25064 | $1,488 | $1,525 | $1,488 |
| White, not Hispanic B03002 | 30.0% | 58.5% | 61.9% |
| Black B03002 | 27.6% | 13.0% | 9.8% |
| Hispanic or Latino B03002 | 31.0% | 19.5% | 18.3% |
| Asian B03002 | 5.2% | 4.5% | 4.7% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.1% |
Economy now FRED unemployment 5.1% in Sep 2026 (4.2% a year earlier); per capita personal income $102,307 in 2025, up 33% in five years (+7.1% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in New Haven, CT.
Comments